title: Vaxfectin adjuvant improves antibody responses of juvenile rhesus macaques to a DNA vaccine encoding the measles virus hemagglutinin and fusion proteins.
abstract: DNA vaccines formulated with the cationic lipid-based adjuvant Vaxfectin induce protective immunity in macaques after intradermal (i.d.) or intramuscular (i.m.) delivery of 0.5 to 1 mg of codon-optimized DNA encoding the hemagglutinin (H) and fusion (F) proteins of measles virus (MeV). To characterize the effect of Vaxfectin at lower doses of H+F DNA, rhesus macaques were vaccinated twice with 20 μg of DNA plus Vaxfectin i.d., 100 μg of DNA plus Vaxfectin i.d., 100 μg of DNA plus Vaxfectin i.m. or 100 μg of DNA plus phosphate-buffered saline (PBS) i.m. using a needleless Biojector device. The levels of neutralizing (P = 0.036) and binding (P = 0.0001) antibodies were higher after 20 or 100 μg of DNA plus Vaxfectin than after 100 μg of DNA plus PBS. Gamma interferon (IFN-γ)-producing T cells were induced more rapidly than antibody, but were not improved with Vaxfectin. At 18 months after vaccination, monkeys were challenged with wild-type MeV. None developed rash or viremia, but all showed evidence of infection. Antibody levels increased, and IFN-γ- and interleukin-17-producing T cells, including cells specific for the nucleoprotein absent from the vaccine, were induced. At 3 months after challenge, MeV RNA was detected in the leukocytes of two monkeys. The levels of antibody peaked 2 to 4 weeks after challenge and then declined in vaccinated animals reflecting low numbers of bone marrow-resident plasma cells. Therefore, Vaxfectin was dose sparing and substantially improved the antibody response to the H+F DNA vaccine. This immune response led to protection from disease (rash/viremia) but not from infection. Antibody responses after challenge were more transient in vaccinated animals than in an unvaccinated animal.
authors.affiliation: W. Harry Feinstone Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.
authors.forename: Wen-Hsuan W
authors.initials: WH
authors.lastname: Lin
authors.forename: Adrian
authors.initials: A
authors.lastname: Vilalta
authors.forename: Robert J
authors.initials: RJ
authors.lastname: Adams
authors.forename: Alain
authors.initials: A
authors.lastname: Rolland
authors.forename: Sean M
authors.initials: SM
authors.lastname: Sullivan
authors.forename: Diane E
authors.initials: DE
authors.lastname: Griffin
mesh_terms: D000276:Adjuvants, Immunologic / Q000008:administration & dosage*; D000818:Animals; D057134:Antibodies, Neutralizing / Q000097:blood; D000914:Antibodies, Viral / Q000097:blood*; D000917:Antibody Formation / Q000276:immunology*; D006389:Hemagglutinins, Viral / Q000235:genetics / Q000276:immunology*; D007371:Interferon-gamma / Q000096:biosynthesis; D020381:Interleukin-17 / Q000096:biosynthesis; D008253:Macaca mulatta / Q000276:immunology*; D008457:Measles / Q000276:immunology / Q000517:prevention & control / Q000821:virology; D008458:Measles Vaccine / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology*; D010714:Phosphatidylethanolamines / Q000008:administration & dosage / Q000276:immunology*; D013601:T-Lymphocytes / Q000276:immunology; D014611:Vaccination; D019444:Vaccines, DNA / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology*; D014760:Viral Fusion Proteins / Q000235:genetics / Q000276:immunology*
chemical_list: D000276:Adjuvants, Immunologic; D057134:Antibodies, Neutralizing; D000914:Antibodies, Viral; D006389:Hemagglutinins, Viral; D020381:Interleukin-17; D008458:Measles Vaccine; D010714:Phosphatidylethanolamines; D019444:Vaccines, DNA; D014760:Viral Fusion Proteins; C032397:hemagglutinin protein G, measles virus; C460866:vaxfectin; D007371:Interferon-gamma
references.citation: Curr Opin HIV AIDS. 2011 May;6(3):221-7
references.pmid: 21399494
references.citation: J Biol Chem. 2002 Aug 30;277(35):32294-301
references.pmid: 12065582
references.citation: Proc Natl Acad Sci U S A. 1993 Dec 1;90(23):11307-11
references.pmid: 8248244
references.citation: Clin Exp Immunol. 1981 Oct;46(1):1-8
references.pmid: 7039877
references.citation: J Med Virol. 2012 May;84(5):763-7
references.pmid: 22431024
references.citation: Nat Med. 2008 Apr;14(4):421-8
references.pmid: 18376406
references.citation: Virology. 1997 Jun 23;233(1):74-84
references.pmid: 9201218
references.citation: MMWR Morb Mortal Wkly Rep. 2007 Nov 30;56(47):1237-41
references.pmid: 18046301
references.citation: Immunology. 2010 Mar;129(3):311-21
references.pmid: 20409152
references.citation: J Immunol. 2011 Jan 15;186(2):745-53
references.pmid: 21148794
references.citation: Curr Opin Immunol. 2011 Oct;23(5):613-9
references.pmid: 21852080
references.citation: Nature. 2000 Aug 24;406(6798):893-7
references.pmid: 10972291
references.citation: J Virol. 2002 Dec;76(24):13034-8
references.pmid: 12438629
references.citation: Nat Rev Genet. 2008 Oct;9(10):776-88
references.pmid: 18781156
references.citation: J Immunol. 2011 Nov 15;187(10):5357-62
references.pmid: 21964025
references.citation: Genet Vaccines Ther. 2006 Feb 15;4:2
references.pmid: 16480501
references.citation: Nat Med. 2003 Jan;9(1):33-9
references.pmid: 12496961
references.citation: J Virol. 2004 Jan;78(1):302-13
references.pmid: 14671112
references.citation: Clin Infect Dis. 2006 Feb 1;42(3):322-8
references.pmid: 16392075
references.citation: PLoS Pathog. 2009 Feb;5(2):e1000295
references.pmid: 19214220
references.citation: J Virol. 2001 May;75(9):4399-401
references.pmid: 11287589
references.citation: J Gen Virol. 2002 Jun;83(Pt 6):1431-1436
references.pmid: 12029158
references.citation: J Virol. 1993 Oct;67(10):6025-32
references.pmid: 8371352
references.citation: J Pediatr. 1977 Nov;91(5):715-8
references.pmid: 909009
references.citation: Lancet. 2012 Jan 14;379(9811):153-64
references.pmid: 21855993
references.citation: Nat Med. 2003 Sep;9(9):1209-13
references.pmid: 12925847
references.citation: J Infect Dis. 1990 Nov;162(5):1036-42
references.pmid: 2230231
references.citation: Vaccine. 2012 Jan 5;30(2):336-41
references.pmid: 22085548
references.citation: Clin Vaccine Immunol. 2008 Aug;15(8):1214-21
references.pmid: 18524884
references.citation: Clin Infect Dis. 2002 Jul 15;35(2):189-96
references.pmid: 12087526
references.citation: Expert Opin Drug Deliv. 2010 Dec;7(12):1433-46
references.pmid: 21118032
references.citation: J Gen Virol. 2012 Jun;93(Pt 6):1305-1315
references.pmid: 22398318
references.citation: Clin Infect Dis. 2007 Dec 1;45(11):1417-24
references.pmid: 17990222
references.citation: Nat Med. 1999 Jun;5(6):629-34
references.pmid: 10371500
references.citation: Immunol Rev. 2010 Jul;236:139-50
references.pmid: 20636814
references.citation: J Infect Dis. 1992 Feb;165(2):262-7
references.pmid: 1730893
references.citation: Hum Vaccin. 2007 Sep-Oct;3(5):157-64
references.pmid: 17637571
references.citation: Vaccine. 2010 Mar 16;28(13):2565-72
references.pmid: 20117262
references.citation: Vaccine. 2004 Jun 2;22(17-18):2261-72
references.pmid: 15149785
references.citation: Cell Mol Life Sci. 2013 Jul;70(13):2271-90
references.pmid: 23052209
references.citation: Virology. 2002 Aug 1;299(2):155-61
references.pmid: 12202217
references.citation: Int J Epidemiol. 2009 Feb;38(1):192-205
references.pmid: 19188207
references.citation: Hum Vaccin Immunother. 2012 Nov 1;8(11):1595-606
references.pmid: 22922766
references.citation: Vaccine. 2006 Mar 10;24(11):1921-7
references.pmid: 16298024
references.citation: Vaccine. 2012 Nov 19;30(49):7046-51
references.pmid: 23041125
references.citation: Proc Natl Acad Sci U S A. 2005 Aug 16;102(33):11581-8
references.pmid: 16037211
references.citation: Proc Natl Acad Sci U S A. 2004 Sep 14;101(37):13601-6
references.pmid: 15342913
references.citation: PLoS Pathog. 2011 Aug;7(8):e1002240
references.pmid: 21901103
references.citation: J Infect Dis. 2007 Jun 15;195(12):1799-807
references.pmid: 17492596
references.citation: Immunity. 2002 Aug;17(2):179-89
references.pmid: 12196289
references.citation: Trends Immunol. 2013 Apr;34(4):151-4
references.pmid: 23266231
references.citation: J Immunol. 2012 Nov 1;189(9):4226-30
references.pmid: 23024280
references.citation: J Exp Med. 2009 Jan 16;206(1):35-41
references.pmid: 19114665
references.citation: Virology. 2000 Oct 10;276(1):202-13
references.pmid: 11022008
references.citation: Clin Pharmacol Ther. 2007 Dec;82(6):672-85
references.pmid: 17971812
references.citation: Hum Gene Ther. 1995 May;6(5):575-90
references.pmid: 7578395
references.citation: J Virol. 2002 Aug;76(15):7460-7
references.pmid: 12097558
references.citation: Viral Immunol. 2003;16(2):183-9
references.pmid: 12828869
references.citation: JAMA. 1998 Aug 12;280(6):527-32
references.pmid: 9707142
references.citation: J Clin Invest. 2003 Jul;112(1):109-17
references.pmid: 12840065
references.citation: J Infect Dis. 1997 Mar;175(3):524-32
references.pmid: 9041322
references.citation: Proc Natl Acad Sci U S A. 2012 Sep 11;109(37):14989-94
references.pmid: 22872860
references.citation: J Clin Immunol. 2010 Mar;30(2):196-203
references.pmid: 20127275
references.citation: Lancet. 2012 Jun 9;379(9832):2173-8
references.pmid: 22534001
references.citation: J Immunol. 2005 Jul 15;175(2):633-9
references.pmid: 16002657
references.citation: Cell Immunol. 2003 Sep;225(1):12-20
references.pmid: 14643300
references.citation: Vaccine. 2001 Feb 28;19(15-16):1911-23
references.pmid: 11228361
references.citation: Cell. 1993 Oct 22;75(2):295-305
references.pmid: 8402913
references.citation: Vaccine. 2006 May 22;24(21):4595-7
references.pmid: 16198452
references.citation: Mucosal Immunol. 2008 Jul;1(4):279-88
references.pmid: 19079189
references.citation: Nat Med. 2000 Jul;6(7):776-81
references.pmid: 10888926
references.citation: Nat Immunol. 2011 Oct 12;12(12):1159-66
references.pmid: 21993848
references.citation: J Virol. 2000 May;74(9):3967-74
references.pmid: 10756008
references.citation: J Virol. 2010 Apr;84(8):3798-807
references.pmid: 20130066
references.citation: J Clin Invest. 2004 Nov;114(9):1241-4
references.pmid: 15520855
references.citation: Trends Immunol. 2012 Jul;33(7):343-9
references.pmid: 22476048
references.citation: Immunol Rev. 2010 Jul;236:125-38
references.pmid: 20636813
references.citation: Hum Vaccin. 2006 Mar-Apr;2(2):45-53
references.pmid: 17012886
references.citation: Nature. 2011 Nov 02;480(7378):530-3
references.pmid: 22048310
references.citation: Nat Rev Microbiol. 2006 Dec;4(12):900-8
references.pmid: 17088933
references.citation: FEMS Microbiol Rev. 2012 May;36(3):649-62
references.pmid: 22316382
references.citation: Immunol Rev. 2010 Sep;237(1):140-59
references.pmid: 20727034
references.citation: Immunol Today. 2000 Apr;21(4):163-5
references.pmid: 10740236